TG & Human Life CORD, Japan Announce Exclusive Partnership
HOUSTON (Nov. 1, 2017) – Human Life CORD Japan, Inc., (HLC) a group company of Nihon Trim (Cord No. 6788, Tokyo Stock Exchange 1st Section) is pleased to announce a strategic agreement with Tissue Genesis, LLC (TG) to distribute its proprietary stem cell processing products in commercial clinics, research institutions, and hospitals in Japan and China. The 10-year agreement marks a major leap forward in advancing the field of regenerative medicine through state-of-the-art point-of-care platform technology, to meet the broad needs of a growing, global healthcare market.
Read the full release in English, Japanese and Chinese PDF formats via the links below: